Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 646
- Registration Number
- NCT02219932
- Locations
- 🇷🇺
Research Site, Nizhny Novgorod, Russian Federation
🇬🇧Research site, Nottingham, United Kingdom
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 104
- Registration Number
- NCT02201849
- Locations
- 🇺🇸
Alkermes Investigational Site, Austin, Texas, United States
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 122
- Registration Number
- NCT02193074
- Locations
- 🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital of Philadelphia - Neurology, Philadelphia, Pennsylvania, United States
🇺🇸UT Southwestern Medical Center/Children's Medical Center Dallas, Dallas, Texas, United States
A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT02171208
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Conditions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 530
- Registration Number
- NCT02159573
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Natalizumab Subcutaneous Immunogenicity and Safety Study
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2
- Registration Number
- NCT02142192
- Locations
- 🇧🇪
Research Site, Liege, Belgium
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT02142205
- Locations
- 🇷🇺
Research Site, Smolensk, Russian Federation
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT02137109
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 214
- Registration Number
- NCT02125604
- Locations
- 🇩🇪
Research Site, Siegen, Germany
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 69
- Registration Number
- NCT02125578
- Locations
- 🇺🇸
Research Site, Phoenix, Arizona, United States